Host and viral determinants of the outcome of exposure to HCV infection genotype 4: A large longitudinal study

American Journal of Gastroenterology

Volumn 109, Issue 2, 2014, Pages 199-211

  Kamal, Sanaa M ^a   Kassim, Samar K ^a   Ahmed, Amany I ^a   Mahmoud, Sara ^a   Bahnasy, Khaled A ^b   Hafez, Tamer A ^c   Aziz, Ibrahiem A ^d   Fathelbab, Iman F ^e   Mansour, Hoda M ^e  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c AMERICAN UNIVERSITY IN CAIRO   (Egypt)

^d AL AZHAR UNIVERSITY   (Egypt)

^e Al Azhar Faculty of Medicine ^*  (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ADULT; AGE DISTRIBUTION; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DISEASE PROGRESSION; EGYPT; FEMALE; GB VIRUS C; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; INTERLEUKINS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 84893813393     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.427     Document Type: Article

References (57)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 13: 107-15.
2. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008: Egyptian: Ministry of Health. El-Zanaty and Associates, and Macro International: Cairo, 2009.
3. Guerra J, Garenne M, Mohamed MK et al. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepatitis 2012; 19: 560-7.
4. Talaat M, El-Sayed N, Kandeel A et al. Sentinel surveillance for patients with acute hepatitis in Egypt, 2001-04. East Mediterr Health J 2010; 16: 134-40.
5. El Gaafary MM, Rekacewicz C, Abdel-Rahman AG et al. Surveillance of acute hepatitis C in Cairo, Egypt. J Med Virol 2005; 76: 520-5.
6. Meky FA, Stoszek SK, Abdel-Hamid M et al. Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin Infect Dis 2006; 42: 628-33.
7. Ray SC, Arthur RR, Carella A et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698-707.
8. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-9.
9. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
10. Santantonio T, Medda E, Ferrari C et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006; 43: 1154-9.
11. Wang CC, Krantz E, Klarquist J et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors infl uencing viral clearance. J Infect Dis 2007; 196: 1474-82.
12. van den Berg CH, Grady BP, Schinkel J et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One 2011; 6: e27555.
13. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in personsm infected with hepatitis C virus. J Exp Med 2000; 191: 1499-512.
14. Th imme R, Oldach KM, Chang R et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395.
15. Th imme RJ, Bukh HC, Spangenberg S et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99: 15661.
16. Cox AL, Mosbruger T, Mao Q et al. Cellular immune selection with hepatitis C virus ersistence in humans. J Exp Med 2005; 201: 1741-52.
17. Cox AL, Mosbruger T, Lauer GM et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005; 42: 104-12.
18. Freeman A, French J, Post C et al. Prevalence of production of virus-specifi c interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis 2004; 190: 1093.
19. Kamal SM, Amin AM, Madwar MA et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004; 78: 12252.
20. Scognamiglio PD, Accapezzato MA, Casciaro A et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999; 162: 6681.
21. Post JJ, Pan Y, Freeman AJ et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189: 1846-55.
22. Mizukoshi E, Eisenbach C, Edlin BR. Hepatitis C virus (HCV)-specifi c immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 2008; 198: 203-12.
23. Th urairajah PH, Hegazy D, Chokshi S. Hepatitis C virus (HCV)-specifi c T-cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis 2008; 198: 1749-1741755.
24. Th ursz M, Yallop R, Goldin R. Infl uence of MHC class II genotype on outcome of infection with hepatitis C virus: the HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354: 2119-24.
25. Knapp S, Hennig BJ, Frodsham AJ. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003; 55: 362-9.
26. Houldsworth A, Metzner M, Rossol S. Polymorphisms in the IL-12B gene and outcome of HCV infection. J Interferon Cytokine Res 2005; 25: 271-6.
27. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
28. Tillmann HL, Thompson AJ, Patel K et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-92.
29. di Iulio J, Ciuffi A, Fitzmaurice K et al. Estimating the net contribution of Interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 2011; 53: 1446-54.
30. Kamal SM, Ismail A, Graham CS et al. Pegylated interferon a therapy in acute hepatitis C: relation to hepatitis C virus specifi c T cell response kinetics. Hepatology 2004; 39: 1721-31.
31. Hosmer DW, Lemeshow S. Applied Logistic Regression. Wiley: New York, 2000.
32. Sharaf Eldin N, Ismail S, Mansour H et al. Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 Weeks of pegylated interferon alfa-2a. PLoS One 2008; 3: 1-7.
33. Saleh DA, Shebl F, Abdel-Hamid M et al. Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. Trans R Soc Trop Med Hyg 2008; 102: 921-8.
34. Talaat M, Kandeel A, El-Shoubary W et al. Occupational exposure to needlestick injuries and hepatitis B vaccination coverage among health care workers in Egypt. Am J Infect Control 2003; 31: 469-74.
35. Mariano A, Scalia Tomba G, Tosti ME et al. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis 2009; 41: 689-99.
36. Page K, Hahn J, Evans J et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200: 1216-26.
37. Santantonio T, Sinisi E, Guastadisegni A et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 2003; 35: 104-13.
38. Bakr I, Rekacewicz C, El Hosseiny M et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut 2006; 55: 1183-7.
39. Saleh DA, Shebl FM, El-Kamary SS et al. Incidence and risk factors for community-acquired hepatitis C infection from birth to 5 years of age in rural Egyptian children. Trans R Soc Trop Med Hyg 2010; 104: 357-63.
40. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-8.
41. Th omson EC, Fleming VM, Main J et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011; 60: 837-45.
42. Kamal SM, Rasenack JW, Bianchi L et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specifi c CD4(+) T-cell and cytokine response. Gastroenterology 2001; 121: 646-56.
43. Spada E, Mele A, Berton A et al. Multispecifi c T cell response and negative HCV-RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut 2004; 53: 1673-81.
44. Smyk-Pearson S, Tester I, Klarquist J et al. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 Help. J Virol 2008; 82: 1827-37.
45. Takaki A, Wiese M, Maertens et al. Cellular immune responses persist and humoral responses decrease two decades aft er recovery from a singlesource outbreak of hepatitis. Nat Med 2000; 6: 578.
46. Riviere Y, Montange T, Janvier G et al. Hepatitis C virus-specifi c cellular immune responses in individuals with no evidence of infection. Virol J 2012; 9: 76.
47. Golden-Mason L, Cox AL, Randall JA et al. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology 2010; 52: 1581-9.
48. Gerlach JT, Diepolder HM, Jung M C et al. Recurrence of hepatitis C virus aft er loss of virus specifi c CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 93341.
49. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011; 60: 1284-93.
50. Kurbanov F, Abdel-Hamid M, Latanich R et al. Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. J Infect Dis 2011; 204: 1391-4.
51. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance. Nature 2009; 461: 399-401.
52. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
53. Moghaddam A, Melum E, Reinton N et al. IL 28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-54.
54. Knapp S, Warshow U, Ho KM et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology 2011; 141: 320-5.
55. Naggie S, Osinusi A, Katsounas A et al. Dysregulation of host innate immunity in HCV genotype 1 infected IL28B CT/TT haplotype patients with depressed viral kinetics and therapeutic response. J Hepatol 2012; 56: 444-54.
56. Dring MM, Morrison MH, McSharry BP et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci USA 2011; 108: 5736-41.
57. Kamal SM, Moustafa KN, Chen J et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43: 923-31.